INDEPENDENT PBM CLIENTS LOWER DRUG PRICES BY 37% IN FIRST YEAR

October 15, 2020

PR Newswire February 11, 2020


The turbulent landscape has fingers pointed in all directions; however, one Pharmacy Benefit Manager (PBM), MC-RX remains diligent is controlling costs and delivering a fresh perspective in otherwise murky waters.

GAINESVILLE, Ga., Feb. 11, 2020 /PRNewswire-PRWeb/ -- Skyrocketing prescription drug prices are enough to make you sick. Just when you thought Big Pharma prices could not get any higher, 471 medications increased an average of 5.1% in the first few days of 2020.


Politicians, lawmakers, and advocates have all stated, "Enough is enough" and vow to prompt legislature to lower drug prices "now." S. 2543, the Prescription Drug Pricing Reduction Act of 2019 (PDPRA), is a bill that proposes reductions in Medicare reinsurance payments from 80% to 20% over a three-year period. This does, however, increase insurers' shares of cost responsibility from 15% to 60%. So, what are the actual savings?


This increase in insurer responsibility has forced more Prescription Benefit Managers to take a closer look. "Consumers are fed up with high prescription drug prices," says LaMar Williams, MC-Rx Executive Vice President. "They should choose a privately held healthcare technology company as an authority on the continuing debate over drug pricing, not another Big Pharma multinational corporation. With a combined 50 years of experience, MC-Rx provides the best, lowest cost PBM system and services available with demonstrated savings of up to 37% in its first year among its network of over 70,000 pharmacies."


"Furthermore," he continues, "Unlike most other PBMs, MC-Rx is one of a very small number of PBM's that owns and operates its own system. This enables great flexibility in benefit plan design and system coding to create a reduced-cost model, which translates to lower prescription drug prices. Above all, we offer independence, transparency, openness, and accountability so plan sponsors may provide better health, every day."


Big Pharma vs. One PBM


Political outrage is running high against Big Pharma drug prices and their "broken promise" to lower or offer generics at a discount.(1) Both major political parties have promised to lower drug prices, only to rise yet again this past January.(2) Even if out-of-pocket costs for Medicare Part D beneficiaries become law in 2020 though S. 2543 (PDPRA), there is still a high annual out-of-pocket spending cap of $3,100 starting in 2022.(3)


A recent study confirmed that "…PBMs are able to obtain lower prices because of their specialized knowledge, negotiation ability, and volume of covered lives, giving them substantial leverage over pharmacies and pharmaceutical companies…" but the ongoing finger-pointing continues to result in an apparent inertia to move any initiatives forward.(4) How long will it take to accomplish any of these goals in today's volatile healthcare environment?


The Solution is a PBM Independent of Outside Influence


"MC-Rx provides faster, more cost-effective services and solutions customized to its clients' needs," adds Williams. "As an independent and transparent PBM with over 70,000 pharmacies in its network, clients' drug spending has been kept below the national growth rates for the past ten years in a row. That speaks volumes about our low drug pricing and how we hold Big Pharma accountable."


One client said it best: "We decided that we needed to make dramatic changes in our pharmacy benefits, and our PBM really wasn't helping us. When we implemented, we used all of MC-Rx's savings tools, and without much disruption at all to our Union members, we saved 37% on our total drug spend and our members saved about 24% on their copays in the first year." ~Trust Fund Administrator


"The bottom line is that MC-Rx is focused on being the best Pharmacy Benefit Manager in the business. We have the most flexible, technologically superior, integrated systems for prescription benefit administration. With our state-of-the-art online solutions, growing network of pharmacies, mail order pharmacy, and ProCare HospiceCare, our customers are able to measure and manage their businesses in real-time, all the time, anywhere."


About MC-Rx


MC-Rx is a full-service Pharmacy Benefit Manager (PBM), with corporate offices in Gainesville, Georgia and Caguas, Puerto Rico, focusing on transparency, best-in-class service, and offering clients "lowest net cost" pricing. MC-Rx was formed by combining two URAC-certified, world class PBMs - ProCare Pharmacy Benefit Manager and mc-21. The ProCare companies were founded in 1988 with the vision of providing innovative computer software systems and services to various sectors of the healthcare industry. ProCare processed their first pharmacy claim in 1994 using their proprietary, internally developed and managed systems, and expanded in 1998 to full-service pharmacy benefit management through the acquisition of NextGen PBM. Today, the ProCare companies also include two affiliated mail-order and specialty pharmacies, ProCare PharmacyCare, and are one of only four PBM providers that own all of their component systems. MC-Rx now provides comprehensive, industry-leading service to clients in Puerto Rico and the U.S.


Brannon, Ike (Jack Kemp Foundation) and Tony LoSasso (DePaul University). INSIGHT: Constraining Pharmacy Benefit Managers Will Not Reduce Drug Prices (January 6 2020). Bloomberg Law – Big Law Business. biglawbusiness.com/insight-constraining-pharmacy-benefit-managers-will-not-reduce-drug-prices.

2. Rowland, Christopher, "Under fire over high prices, Eli Lilly promised cheaper insulin in 2019. The result has some senators steamed", Washington Post, December 29, 2019, washingtonpost.com/business/economy/under-fire-over-high-prices-eli-lilly-promised-cheaper-insulin-in-2019-the-result-has-some-senators-steamed/2019/12/26/6c440b44-204e-11ea-86f3-3b5019d451db_story.html.

3. Luhby, Tami, "Democrats and Republicans promised to lower drug prices. Instead they've gone up again," CNN, January 5, 2020, cnn.com/2020/01/05/politics/2020-drug-price-increases/index.html.

4. Cohen, Joshua, "Prescription Drug Pricing Reduction Act may become law in 2020", Forbes, December 15, 2019, forbes.com/sites/joshuacohen/2019/12/15/prescription-drug-pricing-reduction-act-may-become-law-in-2020/#7e10e08d5537.

A stethoscope is laying on a piece of paper next to a pen
December 12, 2024
URAC accreditation reflects ProCare Rx’s commitment to achieving and maintaining the highest quality, member engagement and experience, and operational standards for PBMs in the industry
By Mc-Rx Team November 15, 2024
Mental health parity and medication adherence
By MC-Rx Clinical Team August 7, 2024
Understanding GLP-1 Medications The landscape of obesity management is evolving, with GLP-1 receptor agonist (RA) medications emerging as a significant player. These FDA-approved drugs have proven effective in helping individuals lose weight, prompting a shift in how they are viewed and covered by health plans. However, the cost implications and strategic decisions surrounding these medications require careful consideration by employer groups and their members. The Case for GLP-1 Medications GLP-1 RAs, originally developed for diabetes management, have shown remarkable efficacy in weight loss. With the growing prevalence of obesity and its associated healthcare costs, there's increasing pressure on health plans to cover these medications. Despite their high cost—annual retail pharmacy expenses can exceed $10,000 per patient—GLP-1 RAs offer potential downstream savings by reducing obesity-related comorbidities such as diabetes, hypertension, and cardiovascular disease​​. Balancing Coverage and Cost Historically, weight loss medications were deemed "lifestyle" drugs and excluded from coverage. However, the rising popularity of GLP-1 RAs and their demonstrated benefits are challenging this perspective. For plan sponsors, the decision to cover these medications involves balancing the high upfront costs with the potential for long-term savings on medical expenses related to obesity. Cost-Containment Strategies For payers choosing to cover GLP-1 medications, several cost-containment strategies can be employed: Formulary Management : Deciding on the placement of these medications within the formulary is crucial. Options range from not covering the drugs to placing them on a high-cost tier with patient cost-sharing. Prior Authorization and Step Therapy : Implementing these measures ensures that only patients with a proper diagnosis (e.g., ICD-10 code for obesity) access these medications, preventing misuse and overutilization. Prerequisite Programs : Requiring participation in wellness or nutrition programs before approving weight loss medications can encourage lifestyle modifications that complement pharmacological treatment. Specialist Restrictions : Limiting prescriptions to weight loss specialists, such as bariatric doctors or endocrinologists, ensures appropriate therapy and monitoring. Duration Limits : Establishing treatment guidelines, such as discontinuing medications if a target weight loss is not achieved within six months, helps manage long-term costs​​. The Role of Brokers and Employer Groups Brokers play a pivotal role in guiding employer groups through the complexities of covering GLP-1 medications. Understanding the cost-benefit dynamics and available cost-containment strategies enables brokers to provide informed recommendations that align with their clients' financial and health objectives. Employer groups, in turn, must weigh the potential benefits of covering these medications against their budgetary constraints and the overall well-being of their workforce. Member Education and Engagement Effective communication with members is essential to ensure they understand the coverage options and adhere to prescribed treatments. Educational initiatives can include: Patient Communication Programs : Providing information on medication adherence, compliance, and lifestyle modifications. Continuing Education : Ongoing programs to keep members informed about the benefits and proper use of weight loss medications. Monitoring and Support : Utilizing pharmacy and medical data to track outcomes and adjust strategies as needed​​. Balance the Scale with Expert Guidance from MC-Rx The adoption of GLP-1 medications for weight loss represents a significant advancement in obesity management. However, the high costs associated with these drugs necessitate careful planning and strategic implementation by brokers, employer groups, and members. By employing robust cost-containment strategies and prioritizing member education, health plans can navigate the financial challenges while delivering meaningful health benefits to their populations. MC-Rx, as a full-service pharmacy benefits manager, offers the expertise and tools to help clients optimize their coverage decisions and manage the complexities of incorporating GLP-1 medications into their health plans. Here are just a few of the GLP-1 strategies we use to shield our clients from excessive costs: Implementation of Drug Management Tools, which is critical to ensure proper utilization for GLP-1s. Strategic Benefit Design, which also protects clients from improper GLP-1 utilization. Clear Member Communication, which is crucial for proper adherence and compliance. When implemented with an existing client, the above-listed strategies helped them achieve $382,000 in cost avoidance for GLP-1s. With the right approach, the benefits of these medications can be realized, contributing to better health outcomes and potentially lowering overall healthcare costs in the long run. For more information on managing GLP-1 medications and other pharmacy benefits, reach out to an MC-Rx expert today .
By MC-Rx Clinical Team August 2, 2024
Mental Health Parity and Medication Adherence
March 21, 2024
MC-Rx, powered by ProCare Rx, has been notified by the Academy of Managed Care Pharmacy (AMCP) of the acceptance of their abstract, “Improving Adherence to HIV PREP via a PBM-Driven Educational Intervention” , for presentation at AMCP 2024 Conference in April.
February 23, 2024
Exploring the rising costs and demands of weight-loss medication and how to combat those costs, significantly lowering drug costs for payors and increasing access for patients who need them.
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 10, 2024
To decrease the burden on healthcare costs, at MC-Rx we strive to create awareness by educating our community regarding the importance of prevention.
September 28, 2023
Increased medication adherence has been linked to better clinical and financial outcomes.
More Posts
Share by: